{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:32:10Z","timestamp":1791055930809,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.autrev.2010.03.003","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T08:42:05Z","timestamp":1269506525000},"page":"553-559","source":"Crossref","is-referenced-by-count":26,"title":["Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products"],"prefix":"10.1016","volume":"9","author":[{"given":"Hakan M.","family":"G\u00fcrcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derin B.","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Razzaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2010.03.003_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1345\/aph.1K037","article-title":"Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders","volume":"41","author":"G\u00fcrcan","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2010.03.003_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tips.2004.04.002","article-title":"Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?","volume":"25","author":"Bayry","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2010.03.003_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.intimp.2004.02.011","article-title":"Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency","volume":"4","author":"de Gracia","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2010.03.003_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib5","first-page":"239","article-title":"The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID)","volume":"47","author":"Bayrakci","year":"2005","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.autrev.2010.03.003_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2010.03.003_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/jaut.2000.0472","article-title":"Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents","volume":"16","author":"Bouvet","year":"2001","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2010.03.003_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/jaut.1995.0032","article-title":"Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies","volume":"8","author":"Vassilev","year":"1995","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2010.03.003_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1006\/jaut.1993.1056","article-title":"Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases","volume":"6","author":"Hurez","year":"1993","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2010.03.003_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/jaut.1993.1057","article-title":"Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg","volume":"6","author":"Masson","year":"1993","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2010.03.003_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/jaut.1994.1039","article-title":"Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use","volume":"7","author":"Caccavo","year":"1994","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2010.03.003_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIg perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2010.03.003_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaut.2007.07.011","article-title":"Physiopathology of natural auto-antibodies: the case for regulation","volume":"29","author":"Zelenay","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2010.03.003_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.intimp.2005.11.005","article-title":"IGIV: contents, properties, and methods of industrial production\u2013evolving closer to a more physiologic product","volume":"6","author":"Martin","year":"2006","journal-title":"Int Immunopharmacol"},{"issue":"4 Suppl","key":"10.1016\/j.autrev.2010.03.003_bib15","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","article-title":"In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations\u2014a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases","volume":"12","author":"Krause","year":"2002","journal-title":"Transfus Med"},{"key":"10.1016\/j.autrev.2010.03.003_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.intimp.2005.11.005","article-title":"IGIV: contents, properties, and methods of industrial production\u2013evolving closer to a more physiologic product","volume":"6","author":"Martin","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2010.03.003_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.autrev.2010.03.003_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","article-title":"Richert DS et al The separation of antibodies, isoagglutinins, prothrombin, plasminogen, and beta-1-lipoprotein into subfractions of human plasma","volume":"71","author":"Oncley","year":"1949","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.autrev.2010.03.003_bib20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/hlca.19540370327","article-title":"Vereinfachtes Verfahren zur Gewinnung vonhumanem Albumin und gamm-Globulin aus Blutplasma mittels Alkoholf\u00e4llung","volume":"37","author":"Nitschmann","year":"1954","journal-title":"Helv Chim Acta"},{"key":"10.1016\/j.autrev.2010.03.003_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1423-0410.1962.tb03274.x","article-title":"Large scale production of human plasma fractions","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2010.03.003_bib22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJM199412153312402","article-title":"Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin","volume":"331","author":"Bj\u00f8ro","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.03.003_bib23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.276.19.1563","article-title":"Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study","volume":"276","author":"Bresee","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2010.03.003_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1423-0410.2007.01016.x","article-title":"A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity","volume":"94","author":"Poelsler","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2010.03.003_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.intimp.2005.11.004","article-title":"Safety considerations in IGIV utilization","volume":"6","author":"Siegel","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2010.03.003_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1423-0410.2003.00279.x","article-title":"Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process","volume":"84","author":"Trejo","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2010.03.003_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biologicals.2005.11.007","article-title":"CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline)","volume":"34","author":"Truchot","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.autrev.2010.03.003_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1423-0410.2006.00829.x","article-title":"Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins","volume":"91","author":"Thyer","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2010.03.003_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2003.08.004","article-title":"Partitioning of TSE infectivity during ethanol fractionation of human plasma","volume":"32","author":"Gregori","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.autrev.2010.03.003_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0140-6736(93)90563-V","article-title":"Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations","volume":"341","author":"Blasczyk","year":"1993","journal-title":"Lancet"},{"issue":"9097","key":"10.1016\/j.autrev.2010.03.003_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0140-6736(05)78212-X","article-title":"Intravenous immunoglobulins and transforming growth factor beta","volume":"351","author":"Kekow","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2010.03.003_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2006.11.005","article-title":"Biologically active anti-nerve growth factor antibodies in commercial intravenous gammaglobulin","volume":"28","author":"Warrington","year":"2007","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2010.03.003_bib33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.autrev.2008.03.015","article-title":"Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg)","volume":"7","author":"von Gunten","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.03.003_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","article-title":"Adverse events associated with intravenous immunoglobulin therapy","volume":"6","author":"Hamrock","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2010.03.003_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.autrev.2010.03.003_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.03.003_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2010.03.003_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archderm.142.2.213","article-title":"Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature","volume":"142","author":"Vecchietti","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2010.03.003_bib40","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4065\/72.12.1151","article-title":"Intravenous immunoglobulin-induced lichenoid dermatitis: a unique adverse reaction","volume":"72","author":"Yockey","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2010.03.003_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000018259","article-title":"A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis","volume":"199","author":"Barbaud","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2010.03.003_bib42","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1345\/aph.1K198","article-title":"Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid","volume":"41","author":"G\u00fcrcan","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2010.03.003_bib43","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ajhp\/62.7.720","article-title":"Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis","volume":"62","author":"Shah","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.autrev.2010.03.003_bib44","unstructured":"Center for Biologics Evaluation and Research. Important Drug Warning. http:\/\/www.fda.govImedwatch\/safety\/1998\/igiv.htm."},{"key":"10.1016\/j.autrev.2010.03.003_bib45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2010.03.003_bib46","first-page":"953","article-title":"Adverse reactions of intravenous immunoglobulin","volume":"21","author":"Al-Wahadneh","year":"2000","journal-title":"Saudi Med J"},{"key":"10.1016\/j.autrev.2010.03.003_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000056085","article-title":"Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases","volume":"62","author":"Sherer","year":"2001","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2010.03.003_bib48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.thj.6200303","article-title":"Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP","volume":"4","author":"Colovic","year":"2003","journal-title":"Hematol"},{"key":"10.1016\/j.autrev.2010.03.003_bib49","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2013a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2010.03.003_bib50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2010.03.003_bib51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3476(97)70355-X","article-title":"Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G","volume":"130","author":"Kattamis","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2010.03.003_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/adc.2003.026575","article-title":"Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children","volume":"89","author":"Balfour-Lynn","year":"2004","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.autrev.2010.03.003_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/clim.1999.4714","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma","volume":"91","author":"Kishiyama","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib54","series-title":"Cecil Essentials of Medicine","first-page":"641","article-title":"Infections of the nervous system","author":"Carpenter","year":"1993"},{"key":"10.1016\/j.autrev.2010.03.003_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1568008033340243","article-title":"Drug-induced aseptic meningitis","volume":"3","author":"Nettis","year":"2003","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1016\/j.autrev.2010.03.003_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14740338.4.2.285","article-title":"Drug-induced aseptic meningitis","volume":"4","author":"Hopkins","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2010.03.003_bib57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venous and arterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.autrev.2010.03.003_bib58","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2010.03.003_bib59","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0140-6736(92)90806-E","article-title":"Effect of high-dose intravenous immunoglobulin therapy on blood rheology","volume":"339","author":"Reinhart","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2010.03.003_bib60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/jnnp.68.6.790","article-title":"Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome","volume":"68","author":"Turner","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2010.03.003_bib61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2010.03.003_bib62","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1191\/0961203303lu2168rr","article-title":"Review: intravenous immunoglobulin therapy and thromboembolic complications","volume":"14","author":"Katz","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2010.03.003_bib63","unstructured":"The FDA Safety Information and Adverse Event Reporting Program. 2002 Safety Alert \u2014 Immune Globulin Intravenous (Human) (IGIV). http:\/\/www.fda.govicber\/infosheets\/igiv082702.htm."},{"issue":"1","key":"10.1016\/j.autrev.2010.03.003_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/jaut.1999.0302","article-title":"In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration","volume":"13","author":"Kessary-Shoham","year":"1999","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2010.03.003_bib65","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","article-title":"Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA","volume":"314","author":"Burks","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.03.003_bib66","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/0140-6736(90)92374-Q","article-title":"Anaphylaxis with intravenous gammaglobulin","volume":"336","author":"McCluskey","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2010.03.003_bib67","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/00365516509077057","article-title":"Studies on the serum gamma-A-globulin level. 3. The frequency of A-gamma-A-globulinemia","volume":"17","author":"Bachmann","year":"1965","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.autrev.2010.03.003_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-3083.2005.01568.x","article-title":"The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used","volume":"61","author":"Djoumerska","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib69","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1423-0410.2008.001036.x","article-title":"Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin","volume":"94","author":"Reipert","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2010.03.003_bib70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2249.2006.03098.x","article-title":"IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice","volume":"145","author":"Vassilev","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/shk.0b013e318123e5a6","article-title":"Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia","volume":"29","author":"Hoffman","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.autrev.2010.03.003_bib72","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/clim.2001.5061","article-title":"Pemphigus vulgaris: The role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production","volume":"100","author":"Bhol","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib73","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib74","first-page":"211","article-title":"Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG","volume":"79","author":"Andersson","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2010.03.003_bib75","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cyto.2007.12.007","article-title":"Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy","volume":"41","author":"Keskin","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2010.03.003_bib77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.03.018","article-title":"Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis","volume":"152","author":"Reinhold","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1423-0410.2002.00186.x","article-title":"A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma","volume":"83","author":"Matejtschuk","year":"2002","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2010.03.003_bib79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/507037","article-title":"Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome","volume":"43","author":"Schrage","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2010.03.003_bib80","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s10067-007-0694-y","article-title":"Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases","volume":"26","author":"Tufan","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.03.003_bib81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2010.03.003_bib82","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1345\/aph.18305","article-title":"Acute renal failure after large doses of intravenous immune globulin","volume":"33","author":"Haskin","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2010.03.003_bib83","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0272-6386(96)90505-3","article-title":"Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis","volume":"28","author":"Hansen-Schmidt","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2010.03.003_bib84","first-page":"347","article-title":"Acute renal failure after intravenous immunoglobulin therapy","volume":"21","author":"Pasatiempo","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.03.003_bib85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archneur.1993.00540020015010","article-title":"Acute renal failure resulting from intravenous immunoglobulin therapy","volume":"50","author":"Tan","year":"1993","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2010.03.003_bib86","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1345\/aph.1K198","article-title":"Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid","volume":"41","author":"G\u00fcrcan","year":"2007","journal-title":"Ann Pharmacother"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210000595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210000595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T05:31:35Z","timestamp":1635139895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997210000595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1568997210000595"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2010.03.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}